Literature DB >> 10913174

TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor.

J C Arevalo1, B Conde, B L Hempstead, M V Chao, D Martin-Zanca, P Perez.   

Abstract

The extracellular region of the nerve growth factor (NGF) receptor, TrkA, contains two immunoglobulin (Ig)-like domains that are required for specific ligand binding. We have investigated the possible role of these two Ig-like domains in receptor dimerization and activation by using different mutants of the TrkA extracellular region. Deletions of each Ig-like domain, of both, and of the entire extracellular region were made. To probe the structural constraints on ligand-independent receptor dimerization, chimeric receptors were generated by swapping the Ig-like domains of the TrkA receptor for the third or fourth Ig-like domain of c-Kit. We also introduced single-amino-acid changes in conserved residues within the Ig-like domains of TrkA. Most of these TrkA variants did not bind NGF, and their expression in PC12nnr5 cells, which lack endogenous TrkA, promoted ligand-independent neurite outgrowth. Some TrkA mutant receptors induced malignant transformation of Rat-1 cells, as assessed by measuring proliferation in the absence of serum, anchorage-independent growth, and tumorigenesis in nude mice. These mutants exhibited constitutive phosphorylation and spontaneous dimerization consistent with their biological activities. Our data suggest that spontaneous dimerization of TrkA occurs when the structure of the Ig-like domains is altered, implying that the intact domains inhibit receptor dimerization in the absence of NGF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913174      PMCID: PMC86068          DOI: 10.1128/MCB.20.16.5908-5916.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

Review 1.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

2.  Expression of functional nerve growth factor receptors after gene transfer.

Authors:  B L Hempstead; L S Schleifer; M V Chao
Journal:  Science       Date:  1989-01-20       Impact factor: 47.728

3.  Molecular and biochemical characterization of the human trk proto-oncogene.

Authors:  D Martin-Zanca; R Oskam; G Mitra; T Copeland; M Barbacid
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

4.  High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors.

Authors:  D Mahadeo; L Kaplan; M V Chao; B L Hempstead
Journal:  J Biol Chem       Date:  1994-03-04       Impact factor: 5.157

5.  Structural basis for FGF receptor dimerization and activation.

Authors:  A N Plotnikov; J Schlessinger; S R Hubbard; M Mohammadi
Journal:  Cell       Date:  1999-09-03       Impact factor: 41.582

6.  Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain.

Authors:  F Coulier; R Kumar; M Ernst; R Klein; D Martin-Zanca; M Barbacid
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

7.  A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors.

Authors:  R Schneider; M Schweiger
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

8.  Nerve growth factor mediates signal transduction through trk homodimer receptors.

Authors:  S Jing; P Tapley; M Barbacid
Journal:  Neuron       Date:  1992-12       Impact factor: 17.173

9.  PC12 cell mutants that possess low- but not high-affinity nerve growth factor receptors neither respond to nor internalize nerve growth factor.

Authors:  S H Green; R E Rydel; J L Connolly; L A Greene
Journal:  J Cell Biol       Date:  1986-03       Impact factor: 10.539

10.  Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain.

Authors:  T van Daalen Wetters; S A Hawkins; M F Roussel; C J Sherr
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more
  29 in total

1.  A unique pathway for sustained neurotrophin signaling through an ankyrin-rich membrane-spanning protein.

Authors:  Juan Carlos Arévalo; Hiroko Yano; Kenneth K Teng; Moses V Chao
Journal:  EMBO J       Date:  2004-05-27       Impact factor: 11.598

2.  Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.

Authors:  Sung-Wuk Jang; Masashi Okada; Iqbal Sayeed; Ge Xiao; Donald Stein; Peng Jin; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

3.  The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability.

Authors:  Antonietta Rosella Farina; Antonella Tacconelli; Lucia Cappabianca; Gesilia Cea; Sonia Panella; Antonella Chioda; Alessandra Romanelli; Carlo Pedone; Alberto Gulino; Andrew Reay Mackay
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 4.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

5.  The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.

Authors:  Gabriele Ugolini; Sara Marinelli; Sonia Covaceuszach; Antonino Cattaneo; Flaminia Pavone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-14       Impact factor: 11.205

6.  A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist.

Authors:  Fouad Brahimi; Jing Liu; Andrey Malakhov; Shafinaz Chowdhury; Enrico O Purisima; Ljubica Ivanisevic; Antoine Caron; Kevin Burgess; H Uri Saragovi
Journal:  Biochim Biophys Acta       Date:  2010-06-19

7.  Nerve growth factor signals via preexisting TrkA receptor oligomers.

Authors:  Paul S Mischel; Joy A Umbach; Sepehr Eskandari; Shane G Smith; Cameron B Gundersen; Guido A Zampighi
Journal:  Biophys J       Date:  2002-08       Impact factor: 4.033

8.  Ubiquitin-specific Protease 36 (USP36) Controls Neuronal Precursor Cell-expressed Developmentally Down-regulated 4-2 (Nedd4-2) Actions over the Neurotrophin Receptor TrkA and Potassium Voltage-gated Channels 7.2/3 (Kv7.2/3).

Authors:  Begoña Anta; Carlos Martín-Rodríguez; Carolina Gomis-Perez; Laura Calvo; Saray López-Benito; Andrés A Calderón-García; Cristina Vicente-García; Álvaro Villarroel; Juan C Arévalo
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157

9.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals.

Authors:  Dianjun Chen; Fouad Brahimi; Yu Angell; Yu-Chin Li; Jennifer Moscowicz; H Uri Saragovi; Kevin Burgess
Journal:  ACS Chem Biol       Date:  2009-09-18       Impact factor: 5.100

10.  A novel p75 neurotrophin receptor-related protein, NRH2, regulates nerve growth factor binding to the TrkA receptor.

Authors:  Simon S Murray; Pilar Perez; Ramee Lee; Barbara L Hempstead; Moses V Chao
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.